- Report
- January 2026
- 196 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- August 2026
- 191 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- July 2026
- 115 Pages
Global
From €4259EUR$4,750USD£3,639GBP
- Report
- October 2025
- 160 Pages
Global
From €2833EUR$3,160USD£2,421GBP
€3542EUR$3,950USD£3,026GBP
- Report
- October 2025
- 160 Pages
Global
From €2833EUR$3,160USD£2,421GBP
€3542EUR$3,950USD£3,026GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,182USD£3,095GBP
- Report
- August 2026
- 291 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- April 2026
- 200 Pages
Global
From €2681EUR$2,990USD£2,291GBP
- Report
- June 2026
- 150 Pages
Global
From €5335EUR$5,950USD£4,558GBP
- Report
- June 2026
- 198 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- June 2026
- 199 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- June 2026
- 197 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 194 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 182 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 191 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 199 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 198 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- January 2026
- 193 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more